Notice for dostarlimab (GlaxoSmithKline Australia Pty Ltd)
Active ingredients
dostarlimab
Date of review outcome
Lapse date
Type
Priority review
Indication
JEMPERLI is indicated in combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite high (MSI-H) endometrial cancer.
Therapeutic area
Oncology